#USA #Aignostics #Berlin and New York #AI Products #HETA Clinical

Aignostics Launches HETA Clinical: A New Era in Pathology

Aignostics, a trailblazer in artificial intelligence for pathology, has made a significant leap in cancer diagnosis by unveiling HETA Clinical, a new suite of AI products designed to streamline pathology workflows and alleviate the issue of failed molecular tests. This innovative family of products spans the entire pathology process, from patient intake and evaluation to molecular testing, ultimately contributing to more efficient and accurate diagnoses across various cancer types.

Revolutionizing Pathology Workflows

In typical pathology environments, the evaluation of slides is often a labor-intensive and time-consuming process. Traditional methodologies rely heavily on visual inspection, leading to variations in diagnosis and a notable incidence of failure in molecular tests. According to estimates from leading pathologists at academic medical centers and precision medicine labs, between 10% and 20% of molecular tests fail because the sampled tissue lacks sufficient tumor material, resulting in redundant biopsies and extended waiting periods for patients.

HETA Clinical addresses these challenges head-on by providing four key products:

1. HETA Quality Control: This product assesses slide quality prior to analysis, swiftly identifying various quality issues that could affect results.
2. HETA Tumor Detect: It highlights tumor regions within slides, prioritizing cases likely to contain tumor material for immediate attention, thereby expediting the diagnostic process.
3. HETA Mitosis: This component accurately counts mitoses, offering a consistent and reproducible mitotic count critical for cancer evaluation.
4. HETA Tumor Cellularity: Focusing on tumor cell content, it not only quantifies cells but also suggests regions with adequate tumor material for molecular analysis.

The Impact of HETA Clinical

With HETA Clinical, Aignostics aims to radically reshape laboratory workflows. As Dr. Rosemarie Krupar, VP of Pathology at Aignostics, articulately declares, "HETA Clinical provides labs a streamlined pathway through their workload." The advent of AI allows for quantification of vital metrics, like tumor presence and mitotic count, with greater accuracy and consistency than manual evaluation, ensuring pathologists can dedicate their expertise where it is most needed.

In a recent validation study, the classification of cells using HETA technology matched or surpassed that of seasoned pathologists, indicating that AI can play a substantial role in complementing human expertise, especially in complex cancer diagnoses.

Moreover, as HETA encompasses a wide spectrum of cancer types, it means that these AI advancements can be applied across numerous pathology subspecialties, extending far beyond the most commonly encountered cancers.

Future Developments

In addition to the launch of HETA Clinical, Aignostics has also rolled out early access to PathoSearch, an innovative visual search engine designed for pathology case management. It aims to enhance the capabilities of pathologists and streamline the retrieval of relevant case information.

Looking ahead, Aignostics has plans to release additional products under the HETA Clinical umbrella, as well as integrate these innovations with various image management systems, including those developed by Techcyte Fusion®. With such advancements, the future of pathology appears promising, as it combines the efficiencies of technology with the care and precision required for effective patient treatment.

About Aignostics

Founded in 2020 as a spin-off from the esteemed Charité Berlin, one of the leading university hospitals globally, Aignostics is an AI company dedicated to transforming how tissue analysis is performed. Supported by influential investors, including Mayo Clinic, the company operates from Berlin and New York. Its commitment to advancing precision medicine through cutting-edge technology positions Aignostics at the forefront of healthcare innovation.

For more information on HETA Clinical and to request a demo, visit Aignostics' official website or follow them on LinkedIn for the latest updates in pathology and artificial intelligence.